STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Schedule 13G: Lincoln Alternative Holds 1.23M Shares of CELUW

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Lincoln Alternative Strategies LLC reported beneficial ownership of 1,230,769 shares of Celularity Inc. Class A common stock, representing 5.14% of the class based on 23,949,229 shares outstanding as of August 26, 2025. The filing on a Schedule 13G discloses that the reporting person has sole voting and dispositive power over these shares and certifies the holdings were not acquired to change or influence control of the issuer. The document lists the reporting person’s principal address in Miami Beach, FL, and the issuer’s principal executive office in Florham Park, NJ.

Positive

  • Material disclosure of ownership: Reports 1,230,769 shares (5.14%) which is above the 5% SEC reporting threshold
  • Sole voting and dispositive power: The filer reports exclusive authority to vote and dispose of the reported shares
  • Certification of passive intent: The filer certifies the securities were not acquired to change or influence control, aligning with Schedule 13G use

Negative

  • None.

Insights

TL;DR: A 5.14% stake is material enough to merit investor attention but the filer disclaims intent to influence control.

The Schedule 13G shows Lincoln Alternative Strategies LLC holds 1,230,769 Class A shares (5.14%). Ownership is reported as sole voting and dispositive power, which indicates direct control of voting and disposition rights for this block. The filing includes the required Certification that the position was not acquired to influence control, consistent with Schedule 13G use rather than Schedule 13D. For investors, this is a material ownership disclosure that signals a meaningful passive stake without asserted activist intent.

TL;DR: The filer crossed the 5% reporting threshold and used Schedule 13G, declaring no intent to change control.

The report identifies Lincoln Alternative Strategies LLC as a Delaware entity with sole voting and dispositive power over the reported shares. The filing complies with disclosure norms by providing issuer and filer addresses, CUSIP, and the Certification statement that holdings are not for control purposes. Crossing the 5% threshold requires public transparency; the statement’s certification is relevant to governance because it differentiates passive holders from potential activists.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Beneficial ownership percentage based on 23,949,229 shares of the Issuer's Class A common stock issued and outstanding as of August 26, 2025.


SCHEDULE 13G



Lincoln Alternative Strategies LLC
Signature:/s/ Stephen Temes
Name/Title:Stephen Temes/Managing Member
Date:08/27/2025

FAQ

What stake did Lincoln Alternative Strategies LLC report in CELUW?

The filer reported beneficial ownership of 1,230,769 Class A shares, representing 5.14% of the class.

Does the Schedule 13G indicate the filer intends to influence Celularity (CELUW) control?

No. The filing includes a Certification stating the securities were not acquired and are not held to change or influence control of the issuer.

What voting and disposition rights does the filer claim for CELUW shares?

Lincoln Alternative Strategies LLC reports sole voting power and sole dispositive power over the 1,230,769 shares.

What basis was used to calculate the 5.14% ownership percentage?

The percentage is based on 23,949,229 shares of Celularity's Class A common stock outstanding as of August 26, 2025 (as stated in the filing).

Where are the issuer’s and filer’s principal offices listed?

Issuer: 170 Park Avenue, Florham Park, NJ; Filer: 404 Washington Ave., Suite 650, Miami Beach, FL.
Celularity Inc

NASDAQ:CELUW

CELUW Rankings

CELUW Latest News

CELUW Latest SEC Filings

CELUW Stock Data

14.37M
Biotechnology
Pharmaceutical Preparations
Link
United States
FLORHAM PARK